Keyphrases
5-year Survival
13%
Activation-regulated Chemokine
8%
Acute Leukemia
13%
Acute Lymphoblastic Leukemia
67%
Acute Myeloid Leukemia
45%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Aprepitant
13%
Average Annual Percentage Change
15%
Azacitidine
8%
BCP-ALL
11%
Bone Marrow
11%
Cancer Registry
10%
Cancer-related Fatigue
13%
CD123
7%
CD22
10%
Chemotherapy
8%
Childhood Acute Lymphoblastic Leukemia
12%
Children with Cancer
19%
Chimeric Antigen Receptor T-cell Therapy
10%
Chronic Myeloid Leukemia
9%
Classical Hodgkin Lymphoma
10%
Clinical Outcomes
12%
Clinical Trials
12%
Clinically Significant
10%
Clofarabine
8%
Confidence Interval
20%
Differentiated Thyroid Cancer
8%
Down Syndrome
16%
Drug Development
8%
Dutch
30%
European Medicines Agency
9%
Event-free Survival
10%
Gemtuzumab Ozogamicin
19%
Genome Analysis
8%
Hematopoietic Stem Cell Transplantation
15%
Hematopoietic Stem Cells
17%
High Risk
7%
High-risk Neuroblastoma
13%
Hodgkin Lymphoma
10%
Human Plasma
8%
Improved Outcomes
9%
Improved Survival
23%
In Cancer
8%
Incidence Trends
9%
Increased Incidence
8%
Innovative Therapies
8%
KMT2A
19%
Leukemia
28%
Leukemia Patients
22%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
9%
Maintenance Therapy
8%
Medicinal Product Development
8%
Medullary Thyroid Cancer
8%
Minimal Residual Disease
12%
Myelodysplastic Syndrome
9%
Neonate
13%
Netherlands
50%
Neuroblastoma
18%
New Agents
8%
Newly Diagnosed
23%
Nilotinib
8%
Non-Hodgkin Lymphoma
9%
Older Adults
21%
Oncology
14%
Overall Survival
15%
P53 Pathway
8%
Paediatric Strategy Forum
9%
Pediatric
62%
Pediatric Acute Lymphoblastic Leukemia
17%
Pediatric AML
9%
Pediatric Cancer
13%
Pediatric Leukemia
52%
Pediatric Oncology
24%
Pediatric Patients
71%
Pediatric Tumors
7%
Pharmacokinetics
41%
Phase II Study
21%
Population Pharmacokinetics
30%
Population-based Study
13%
Preadolescent children
18%
Precision Oncology
13%
Relapsed or Refractory
26%
Relapsed or Refractory Acute Myeloid Leukemia
13%
Risk Factors
8%
RNA Sequencing (RNA-seq)
7%
Sleep Problems
10%
Sleep-wake Rhythm
8%
Solid Tumors
9%
Survival Rate
8%
T Cells
11%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
14%
Targeted Therapy
8%
Targeted Treatment
8%
Thymus
8%
Treatment Effect
8%
Treatment Response
12%
Trisomy 21
8%
Working Diagnosis
10%
Young Adolescents
22%
Young Cancer Patients
9%
Medicine and Dentistry
Acute Leukemia
10%
Acute Lymphoblastic Leukemia
70%
Acute Myelogenous Leukemia
18%
Acute Myeloid Leukemia
50%
Adolescence
57%
Anaplastic Lymphoma Kinase
7%
Arm
5%
B Cell
6%
Calicheamicin
5%
Cancer
15%
Cancer Registry
10%
Cancer Susceptibility
5%
Cancer-Related Fatigue
8%
Central Nervous System Tumor
7%
Chemotherapy
9%
Childhood Cancer
29%
Chimeric Antigen Receptor T-Cell
6%
Chimeric Antigen Receptor T-Cell Immunotherapy
5%
Chronic Myelogenous Leukemia
5%
Classical Hodgkin Lymphoma
10%
Clinical Trial
12%
Dexamethasone
13%
Diagnosis
8%
Disease
32%
Down Syndrome
15%
Drug Megadose
5%
Event Free Survival
10%
Experimental Therapy
6%
Fusion Gene
5%
Ganglioneuroblastoma
31%
Hematopoietic Cell
10%
Hematopoietic Stem Cell Transplantation
10%
Hodgkin's Lymphoma
11%
Immunity
5%
Immunophenotyping
5%
Immunotherapy
22%
In Vitro
5%
Inotuzumab Ozogamicin
18%
Kidney Tumour
9%
Leukemia
19%
Leukemia Cell
7%
Leukemia in Children
9%
Lymphoblastic Lymphoma
6%
Maintenance Therapy
11%
Malignant Neoplasm
39%
Medicine
9%
Minimal Residual Disease
14%
Molecular Profiling
5%
Mortality Rate
6%
Neoplasm
24%
Non-Hodgkin Lymphoma
6%
Oncology
26%
Overall Survival
24%
Patient with Leukemia
5%
Pediatric Acute Myeloid Leukemia
43%
Pediatric Cancer
14%
Pediatrics
100%
Pediatrics Patient
34%
Personalized Medicine
9%
Phase II Trials
5%
Pilocytic Astrocytoma
5%
Precursor
6%
Progression Free Survival
7%
Randomized Controlled Trial
8%
Retrospective Study
8%
RNA Sequence
5%
Side Effect
9%
Sleep Waking Cycle
8%
Solid Malignant Neoplasm
5%
Somatics
11%
Survival Rate
9%
T Cell
7%
Targeted Therapy
14%
Thymus and Activation Regulated Chemokine
10%
Treatment Response
10%
Tumor Microenvironment
5%
Wilms' Tumor
8%